Bupropion in the treatment of major depressive disorder in real-life practice

Clinical Drug Investigation

Volumn 31, Issue SUPPL. 1, 2011, Pages 19-24

  Sennfelt, Diogo Azevedo Oliveira ^a   Da Silva, Maria Alice Rodrigues Marques ^b   Da Silva Tavares, Anabela Pereira ^c  

^a HOSPITAL GARCIA DE ORTA   (Portugal)

^b Lisbon SAMS Clinical Centre   (Portugal)

^c CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; DIAZEPAM; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR; ZOLPIDEM;

ADULT; ANHEDONIA; ANXIETY; APPETITE DISORDER; ARTICLE; CASE REPORT; DELUSION; DEPRESSION; DRUG DOSE INCREASE; FATIGUE; FEMALE; HUMAN; IMPULSIVENESS; INSOMNIA; LIBIDO DISORDER; MAJOR DEPRESSION; MELANCHOLIA; MENTAL HEALTH CARE; MONOTHERAPY; MYALGIA; OBESITY; OBSESSION; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; PSYCHOTHERAPY; REMISSION; SUICIDE ATTEMPT; TREATMENT OUTCOME; WEAKNESS;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; DEPRESSIVE DISORDER, MAJOR; DOPAMINE UPTAKE INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 80054848566     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/1159617-S0-000000000-00000     Document Type: Article

References (10)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Arlington (VA): American Psychiatric Association, 1994
2. Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology ofMentalDisorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004; (420): 21-7
3. Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 2007; 8 (2): 67-104 (Pubitemid 46690921)
4. Fava M, Rush AJ, Thase ME, et al. 15 Years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 2005; 7 (3): 106-13 (Pubitemid 41783226)
5. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354 (12): 1243-52
6. DeBattista C, Solvason HB, Poirier J, et al. A prospective trial of bupropion SR augmentation of partial and nonresponders to serotonergic antidepressants. J Clin Psychopharmacol 2003; 23 (1): 27-30 (Pubitemid 36164422)
7. Papakostas GI, Nutt DJ, Hallett LA, et al. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry 2006; 60 (12): 1350-5 (Pubitemid 44838537)
8. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62 (6): 617-27 (Pubitemid 40973437)
9. Papakostas GI, Trivedi MH, Alpert JE, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: ameta-analysis of individual patient data from 10 double-blind, randomized clinical trials. J Psychiatr Res 2008; 42 (2): 134-40 (Pubitemid 350061259)
10. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71 (10): 1259-72